CDXS — Codexis, Inc.
Is CDXS overbought or oversold? Here is the current MarketMoodz read.
Codexis, Inc. (CDXS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.06. The rating moved from Strong Oversold to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$1.06
- Last changeMoved from Strong Oversold to Oversold on November 14, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Codexis, Inc. (CDXS) is a small-cap enzyme-engineering company with demonstrated commercial partnerships and a technology platform that addresses biocatalysis needs in pharma and specialty chemicals. Financial performance has been uneven, and the company faces typical small‑cap biotech risks including cash burn, potential dilution, and reliance on a limited set of partners. Near-term upside depends on execution of commercial agreements, achievement of partner milestones, and improved revenue visibility; downside is driven by financing needs, competitive pressures, and low liquidity. Social sentiment and detailed recent filings were not available in the provided data; market tone is generally constructive for growth names, which could modestly support recovery if operational signals improve.
Key factors
- Established enzyme engineering platform with commercial and partnership revenue streams (biocatalysis solutions for pharma and specialty chemicals).
- Recent revenue generation mixed with historically variable quarterly results; company has shown ability to win partnerships but scale to sustained profitability is uncertain.
- Potential near-term catalysts from partnership milestones, new commercial agreements, or expanded adoption of biocatalysis in drug manufacturing.
- Low absolute valuation and depressed share price create asymmetric upside if operational execution or partner-led revenues improve.
- Macroeconomic and sector environment currently constructive for growth areas, which could support selective healthcare/biotech upside in the near term.
- Liquidity and capital-raising history for small-cap biotech/biotech-adjacent names implies potential dilution risk; balance-sheet runway is a key monitoring item.
Risks
- Cash burn and limited runway requiring equity or convertible financings that would dilute existing shareholders.
- Dependence on a small number of partnership agreements or customers; loss or delay of a major partner milestone would materially impact near-term revenue.
- Competitive pressure in enzyme engineering and biologics manufacturing from larger CDMOs and emerging synthetic biology firms.
- Low trading liquidity and high share-price volatility could amplify downside in negative news or broader market stress.
- Regulatory or technical setbacks in commercial deployments or failure of new product adoption by pharmaceutical partners.
- Broader convertible-debt and financing market dynamics that can increase dilution/hedging pressure across mid-/small-cap biotech names.
See today's live rating, score and targets
Members see the live hourly rating for CDXS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.